Cormorant Asset Management, LP, 10% Owner, Director at Turning Point Therapeutics, Inc. (TPTX), bought 400,000 shares at $18.00 ($7.2M) on 2019-04-22, disclosed to the SEC on 2019-04-25.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| DRUG | BUY | 2024-11-06 | $8.0M | — | Filing → |
| EYPT | BUY | 2024-05-08 | $20.2M | — | Filing → |
| CRBP | BUY | 2024-02-06 | $14.3M | — | Filing → |